Skip to main content

Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC).

Publication ,  Conference
Penson, DF; Armstrong, AJ; Concepcion, RS; Wu, K; Wang, F; Krivoshik, AP; Phung, D; Higano, CS
Published in: Journal of Clinical Oncology
January 10, 2016

169 Background: STRIVE was arandomized, double-blind, phase 2 trial comparing ENZA vs BIC in nonmetastatic (M0) or metastatic (M1) CRPC. In this study, ENZA significantly reduced the risk of prostate cancer progression or death compared with BIC in patients with M0 or M1 CRPC. Methods: 396 men with M0 (n = 139) or M1 (n = 257) CRPC were randomized to ENZA 160 mg/day or BIC 50 mg/day. The primary endpoint of PFS was defined as the time from randomization to radiographic progression, PSA progression, or death from any cause, whichever occurred first. rPFS was defined as the time from randomization to death or the first objective evidence of radiographic disease progression in soft-tissue disease per RECIST v1.1 or in bone per PCWG2 guidelines. Sensitivity analyses were prespecified to assess the impact of alternative definitions for PFS in all patients and were performed post hoc for the key secondary endpoint of rPFS in patients with M1 disease only (table). Results: Consistent with the primary analyses of PFS and rPFS, the results from all sensitivity analyses favored ENZA over BIC (table). Conclusions: PFS and rPFS sensitivity analyses in STRIVE demonstrated a consistent and robust treatment benefit with ENZA compared with BIC by any variation of the original definition of PFS. Clinical trial information: NCT01664923. [Table: see text]

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

January 10, 2016

Volume

34

Issue

2_suppl

Start / End Page

169 / 169

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Penson, D. F., Armstrong, A. J., Concepcion, R. S., Wu, K., Wang, F., Krivoshik, A. P., … Higano, C. S. (2016). Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC). In Journal of Clinical Oncology (Vol. 34, pp. 169–169). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.2_suppl.169
Penson, David F., Andrew J. Armstrong, Raoul S. Concepcion, Kenneth Wu, Fong Wang, Andrew P. Krivoshik, De Phung, and Celestia S. Higano. “Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC).” In Journal of Clinical Oncology, 34:169–169. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.169.
Penson DF, Armstrong AJ, Concepcion RS, Wu K, Wang F, Krivoshik AP, et al. Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 169–169.
Penson, David F., et al. “Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC).Journal of Clinical Oncology, vol. 34, no. 2_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 169–169. Crossref, doi:10.1200/jco.2016.34.2_suppl.169.
Penson DF, Armstrong AJ, Concepcion RS, Wu K, Wang F, Krivoshik AP, Phung D, Higano CS. Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 169–169.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

January 10, 2016

Volume

34

Issue

2_suppl

Start / End Page

169 / 169

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences